Andere talen Merck & Co., Inc.

Aandelen

MRK

US58933Y1055

Beurs gesloten - Nyse Andere beurzen 22:00:02 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
125,2 ^USD	-0,13%		-0,75%	+14,85%

15/04	MERCK & CO., INC. : Zacks Investment Research herhaalt koopadvies	ZM
11/04	Merck & Co ontvangt een aandeelhoudersvoorstel van The Bahnsen Family Trust	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Merck Manuals Celebrates Its 125th Year	17/04
Moderna cancer vaccine shows promise in initial tests; share skyrockets	12/04
Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust	11/04
Merck & Co Receives a Shareholder Proposal from National Legal and Policy Center	11/04
Merck & Co Receives a Shareholder Proposal from Kenneth Steiner	11/04
POINT MARCHÉS-Rebond prudent en vue en Europe avant l'inflation américaine	10/04
POINT MARCHÉS-Wall Street marque une pause avant les chiffres de l'inflation	09/04
S&P 500 ends slightly higher as markets brace for inflation data, earnings	09/04
Wall St backs down as markets brace for inflation data, earnings	09/04
Moderna Shares Rise Following Positive Results of Head and Neck Cancer Vaccine in Early Study	09/04
Moderna jumps as personalized cancer vaccine shows benefit in early study	09/04
Geneos cancer vaccine shrinks liver tumors in small trial	07/04
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer	05/04
Boehringer to lay off salespeople as Humira biosimilar sales lag	05/04
Boehringer to lay off salespeople as Humira biosimilar sales lag	05/04
Merck & Co., Inc. acquired Abceutics, Inc. for approximately $210 million.	05/04
Merck Starts Phase 3 Clinical Trial of Potential Lung Cancer Combination Therapy	04/04
Merck : lance un essai de phase III sur le cancer du poumon	04/04
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer	04/04
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer	04/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Merck & Co., Inc.: een melkkoe die de succesproducten verbergt

11 juli 2022 om 11:12 uur